Preclinical Projects

Affimed has built a discovery engine which includes the
generation of TandAbs and Trispecific Abs for its own pipeline
or for the development in the context of partnerships.

 
 
     
 
 
AFM24   About EGFRvIII
 
   
 
AFM24 specifically binds to Epidermal Growth Factor Receptor wild type (EGFRwt) on solid tumor cells. AFM24 is an NK-cell engaging TandAb targeting CD16A. Both targets are bound with high affinity, whereby NK-cells are redirected and activated to kill the cancer cells. AFM24 selectively binds to EGFRwt but not EGFRvIII. Importantly, AFM24 has demonstrated tumor cell killing independent of their mutational status (e.g. ras). AFM24 is in preclinical development for the treatment of solid tumors overexpressing EGFRwt.   The Epidermal Growth Factor Receptor variant III, or EGFRvIII, has been shown to be a highly specific marker for a portion of certain solid tumors including glioblastoma, prostate cancer and head and neck cancer. EGFRvIII is a mutated variant of the wild type EGFR expressed only in certain tumor cells, whereas the wild type receptor is ubiquitously expressed in healthy epithelial tissues. Based on current research, EGFRvIII is not expressed by healthy tissues, which makes it a unique target for a highly potent cancer immunotherapy such as Affimed’s T-cell TandAb, AFM21, or the NK-cell engaging TandAb against EGFRvIII, AFM22.
 
     
 
AFM21 and AFM22   About EGFRwt
 
   
 
AFM21 and AFM22 are investigated as backup candidates for solid tumor indications. Both molecules specifically bind to Epidermal Growth Factor Receptor variant III (EGFRvIII) on solid tumor cells. While AFM21 is a T-cell TandAb targeting CD3, AFM22 is a TandAb targeting CD16A on NK-cells. Both targets are bound with high affinity, whereby T-cells or NK-cells are redirected and activated to kill the cancer cells. Importantly, AFM21 and AFM22 both selectively bind to EGFRvIII but not EGFR. Both programs are in preclinical development for the treatment of solid tumors expressing EGFRvIII.   The Epidermal Growth Factor Receptor wild type (EGFRwt) is ubiquitously expressed in healthy epithelial tissues, but, when constitutively activated through binding by growth factors or mutations, plays an important role in the pathophysiology of numerous solid cancers such as colorectal, lung or head and neck cancer. A number of EGFR-targeting drugs have been approved to treat solid tumors including tyrosine kinase inhibitors and monoclonal antibodies, but despite demonstrated clinical activity, intrinsic or acquired resistance is frequently observed. Displaying significant advances over IgG-based antibodies in recruiting NK-cells, AFM24 has the potential to overcome these limitations.
 
 



Posters
AACR 2016 – AFM24  
 
AFM21  
AACR 2016 – AFM21-22  
   
 
  Impressum Disclaimer